Findings

What do systematic reviews say?

12 questions · 13 findings · 1 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 38.5%Moderate 5 · 38.5%High 3 · 23.1%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Chondroitin with or without glucosamine vs placebo/control · Pain (short‐ and long‐term) Scale from 0 to 100 (lower is better)
  Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 3038 participants
  Low
Direct match · question page
- Chondroitin with or without glucosamine vs placebo/control · Pain (short‐ and long‐term) Scale from 0 to 100 mm (lower is better)
  Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  17 studies · 2262 participants
  Low
Direct match · question page
- Chondroitin vs placebo · Composite Measure of Pain, Function and Disability as
  Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 903 participants
  Moderate
Direct match · question page
- Chondroitin vs placebo · Pain on a 0 to 100 mm scale ‐ Short‐term studies (< 6 months)—dose ≥ 800 mg/d
  Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1077 participants
  Low
Direct match · question page
- Chondroitin with or without glucosamine vs placebo/control · Composite Measure of Pain, Function and Disability as assessed through Lequesne's index Scale from 0 to 24 (lower indicates less pain and disability)
  Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1756 participants
  Low

Chondroitin vs placebo

Pain on a 0 to 100 mm scale ‐ Short‐term studies (< 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1077 participants
Low

Chondroitin vs placebo

Pain on a 0 to 100 scale ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 989 participants
Low

Chondroitin vs placebo

WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

Chondroitin leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term… compared with placebo (high certainty).

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
RR 1.12 [1.01, 1.24]
2 studies · 1253 participants
High

Chondroitin vs placebo

Composite Measure of Pain, Function and Disability as · patients with osteoarthritis

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 903 participants
Moderate

Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d Scale: millimeters (smaller decrease in reduction in minimum joint space width is better) · patients with osteoarthritis

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 922 participants
High

Chondroitin vs placebo

Withdrawals due to adverse events · patients with osteoarthritis

Chondroitin showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
RR 1.08 [0.74, 1.57]
10 studies · 2406 participants
Moderate

Chondroitin vs placebo

Number of serious adverse events · patients with osteoarthritis

Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
OR 0.4 [0.19, 0.82]
6 studies · 954 participants
Moderate

Chondroitin with or without glucosamine vs placebo or control

Composite Measure of Pain, Function and Disability as · patients with osteoarthritis

2 findings from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1756 participants
Low
Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 2334 participants
Moderate

Chondroitin with or without glucosamine vs placebo or control

Pain (short‐ and long‐term) Scale from 0 to 100 (lower is better) · patients with osteoarthritis

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 3038 participants
Low

Chondroitin with or without glucosamine vs placebo or control

Physical function · patients with osteoarthritis

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1163 participants
Moderate

Chondroitin with or without glucosamine vs placebo or control

Pain (short‐ and long‐term) Scale from 0 to 100 mm (lower is better) · patients with osteoarthritis

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 2262 participants
Low

Chondroitin with or without glucosamine vs placebo or control

WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

Chondroitin with or without glucosamine leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) Long‐term… compared with placebo/control (high certainty).

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
RR 1.12 [1.01, 1.24]
2 studies · 1253 participants
High